LIPELLA PHARMACEUTICALS INC. (LIPO)
Lipella Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm specializing in the creation of novel therapies. The company achieves this by repurposing and optimizing the active ingredients found in established generic drugs, tailoring these reformulations for diverse medical applications. Its lead candidate, LP-10, a tacrolimus formulation, is presently in Phase IIa clinical studies, targeting radiation-induced hemorrhagic cystitis. Additionally, LP-310, another tacrolimus-derived compound, is under development for the management of oral lichen planus. Founded in 2005, the company maintains its headquarters in Pittsburgh, Pennsylvania.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Lipella Pharmaceuticals Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 4.62M shares outstanding
USLipella Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm specializing in the creation of novel therapies.
The company achieves this by repurposing and optimizing the active ingredients found in established generic drugs, tailoring these reformulations for diverse medical applications.
Its lead candidate, LP-10, a tacrolimus formulation, is presently in Phase IIa clinical studies, targeting radiation-induced hemorrhagic cystitis.
Additionally, LP-310, another tacrolimus-derived compound, is under development for the management of oral lichen planus. Founded in 2005, the company maintains its headquarters in Pittsburgh, Pennsylvania.
Leadership
Jonathan Kaufman
Co-Founder, Chairman, Chief Executive Officer, President, Secretary & Treasurer
Douglas Johnston
Chief Financial Officer
Janet Okonski
Director of Clinical Operations
Katie Johnston
Controller
Employees
5
Country
US
Sector
Healthcare
Website
lipella.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Kaufman Jonathan H | See remarks below. | Other | 125.8K | -- | Apr 3, 2025 |
| Kaufman Jonathan H | See remarks below. | Other | 4.1K | -- | Apr 3, 2025 |
| Kaufman Jonathan H | See remarks below. | Other | 28.9K | -- | Apr 3, 2025 |
| Kaufman Jonathan H | See remarks below. | Other | 537.0K | -- | Apr 3, 2025 |
| Kaufman Jonathan H | See remarks below. | Other | 10.3K | -- | Mar 13, 2025 |
| Kaufman Jonathan H | See remarks below. | Other | 4.1K | -- | Mar 13, 2025 |
| Name | Shares | % | Source |
|---|---|---|---|
Jonathan H. Kaufman · may incl. warrants· filed Apr 2025 | 212.3K | 4.6% | 13D |
Michael B. Chancellor · may incl. warrants· filed Apr 2025 | 209.6K | 4.5% | 13D |
Leaf Huang · may incl. warrants· filed May 2025 | 69.4K | 1.5% | 13G |
SABBY MANAGEMENT, LLC · may incl. warrants· filed Jan 2025 | 60.3K | 1.3% | 13G |
Michele Gruber · may incl. warrants· filed Nov 2024 | 5.9K | 0.1% | 13G |
Insiders
- Kaufman Jonathan HSee remarks below.
based on 4.62M shares outstanding
US30d Avg
1.41K
60d Avg
1.19K
90d Avg
2.23K